- Organizations: KALA BIO
Business
Leadership watch: KALA BIO names new CEO, Aurion Biotech promotes execs
Aurion makes its move ahead of initiating a phase 3 trial in early 2026 for its allogeneic cell therapy, under evaluation for corneal endothelial disease.
Pipeline
Kala's phase 2b PCED trial fails to meet primary goal
Company plans to cease development of lead asset KPI-012 as the CHASE study also falls short of achieving statistical significance for secondary endpoints.
Pipeline
Favorable preliminary data reported for KIO-301 in RP treatment
Kiora Pharmaceuticals' first-in-human ABACUS study suggests promising vision function restoration.
Pipeline
FDA grants Fast Track designation to KPI-012 for PCED
Kala Pharmaceuticals’ lead product candidate is a human MSC-S therapy.
Pipeline
FDA accepts Kala Pharmaceuticals’ IND application for PCED treatment
The company plans on initiating enrollment for a phase 2b trial this quarter.
Archives